Ciphergen Biosystems, Inc. Establishes Scientific Advisory Board of Distinguished Scientists
June 12 2006 - 10:00AM
PR Newswire (US)
Scientific Advisory Board to Assist in Strategic Management of
Diagnostic Pipeline FREMONT, Calif., June 12 /PRNewswire-FirstCall/
-- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) today announced the
establishment of a Scientific Advisory Board to assist in directing
the Company's product development strategies. Members of the
scientific advisory board are distinguished members of academia and
industry with experience in diagnostic test development and
commercialization. "With the initiation of our scientific advisory
board, Ciphergen has taken another important step towards becoming
a leading provider of molecular diagnostic tests based on novel
proteomics technologies," said Gail S. Page, President and CEO.
"These scientists will meet regularly with our senior management
team to help leverage our intellectual property portfolio, guide
our resource allocation, and evaluate our ongoing diagnostic
programs and prioritize them towards commercialization. Their
collective medical research and diagnostic industry experience is
extraordinary; these scientists can provide insights that help
drive Ciphergen forward into the new era of high value molecular
diagnostics." The scientific advisory board is composed of the
following individuals: -- Robert C. Bast, Jr., MD, is Vice
President for Translational Research and the Harry Carothers Wiess
Distinguished University Professor for Cancer Research at the
University of Texas M.D. Anderson Cancer Center. Dr. Bast is best
known for developing the Ovarian Cancer (OC) 125 monoclonal
antibody that led to the production of the CA125 radioimmunoassay.
Serum CA125 levels have provided the first generally useful marker
for monitoring the course of patients with epithelial ovarian
cancer. CA 125 is currently being evaluated as one component of a
screening strategy for ovarian cancer. Dr. Bast has published more
than 500 articles and chapters, and has edited the textbook Cancer
Medicine. He continues to care for patients with breast and ovarian
cancer and has been listed in the Best Doctors of America and in
America's Top Physicians. Dr. Bast received his B.A. cum laude from
Wesleyan University and his M.D. magna cum laude from Harvard
Medical School. -- Daniel W. Chan, PhD, DABCC, FACB, is Professor
of Pathology, Oncology, Urology and Radiology, Director of Clinical
Chemistry Division, Department of Pathology, and the Director,
Center for Biomarker Discovery at the Johns Hopkins University
School of Medicine. Dr. Chan is an internationally recognized
authority in clinical chemistry, proteomics, immunoassay, and
biochemical tumor markers (particularly breast and prostate cancer
markers). He is particularly well-known as a leader in the concept
and methodology of the clinical usefulness of prostate-specific
antigen (PSA) as a marker for prostate cancer. He has published
over 200 scientific articles, five books on immunoassay automation,
endocrinology, and tumor markers. His research has led to major
findings showing the importance of analytical methodologies of
laboratory testing in diagnosing, managing, and understanding human
cancers. He is the Editor-in-Chief of the journal Clinical
Proteomics. Dr. Chan received his Ph.D. from the State University
of New York at Buffalo -- Ian Jacobs, MD, FRCOG, is Director of the
Department of Gynecological Oncology and of the Institute of
Women's Health at University College London. Professor Jacobs is
recognized as one of Europe's leading academic gynecological
oncologists and is President of the European Society of
Gynaecological Oncologists. His research includes heading the UK
Collaborative Trial of Ovarian Cancer Screening involving 200,000
women in the UK, as well as laboratory studies of the genetic basis
of gynecological cancers. Professor Jacobs' clinical activities and
expertise include the surgical management of gynecological cancer,
management of familial cancer and screening for ovarian and
cervical cancer. Professor Jacobs has authored or co-authored more
than 200 articles, reviews and chapters. He qualified at Cambridge
University and London University before training in clinical
medicine and research in Cambridge, at Duke University and at The
Royal London, St Bartholomew's and Royal Marsden Hospitals in
London. -- Joyce G. Schwartz, MD, is Vice President & Chief
Laboratory Officer of Quest Diagnostics. Dr. Schwartz is
responsible for medical operations and medical quality for the
company's core laboratory testing business. Dr. Schwartz is
board-certified in anatomic and clinical pathology, with many years
of academic and hospital experience. Prior to joining Quest
Diagnostics, Dr. Schwartz held a tenured position as Professor at
the University of Texas Health Science Center at San Antonio. She
received her BS and MA degrees from the University of Texas at
Austin and she received her medical degree from the University of
Texas Health Science Center at San Antonio, where she served as
Chief Resident in Anatomic and Clinical Pathology. Dr. Schwartz has
published over eighty articles in peer-reviewed medical and
scientific publications -- William Wallen, PhD, is Senior Vice
President and Chief Scientific Officer of Idexx Laboratories, a
worldwide leader in innovative products and services for
veterinary, food and water applications. Before joining Idexx, Dr.
Wallen was Senior Vice President and Head, Office of Technology for
the Diagnostics Division of Bayer Healthcare. In his ten years with
Bayer, Dr. Wallen held various senior scientific and leadership
positions, including as Head of Research and Development for
Bayer's laboratory testing and Head of Research for the nucleic
acid diagnostics segment. He has authored or co-authored more than
50 scientific papers and articles covering topics in immunology,
virology, oncology and detection methodologies. Dr. Wallen earned
his bachelor's degree in zoology and his masters in microbiology
from Michigan State University and his doctorate in Molecular
Biology from the University of Arizona College of Medicine. About
Ciphergen Ciphergen is dedicated to translating protein biomarkers
and panels of biomarkers into protein molecular diagnostic tests
that improve patient care. We are also focused on providing
collaborative R&D services through our Biomarker Discovery
Center(R) laboratories for biomarker discovery for new diagnostic
tests as well as pharmacoproteomic services for improved drug
toxicology, efficacy and theranostic assays. Ciphergen develops,
manufactures and markets a family of ProteinChip(R) Systems and
services for clinical, research and process proteomics
applications. ProteinChip Systems enable protein discovery,
validation, identification and assay development to provide
researchers with predictive, multi-marker assay capabilities and a
better understanding of biological function at the protein level.
Additional information about Ciphergen can be found at
http://www.ciphergen.com/. Safe Harbor Statement Note Regarding
Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding Ciphergen's ability to
create and commercialize diagnostic tests that are useful in the
prevention of disease, and the usefulness of the scientific
advisory board in the direction of such efforts. Actual results may
differ materially from those projected in such forward-looking
statements due to various factors, including the risk that
Ciphergen may not be able to develop diagnostic tests based on the
discoveries of certain biomarkers. Investors should consult
Ciphergen's filings with the Securities and Exchange Commission,
including its Form 10-K filed March 17, 2006, for further
information regarding these and other risks related to the
Company's business. NOTE: Ciphergen, ProteinChip and Biomarker
Discovery Center are registered trademarks of Ciphergen Biosystems,
Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue
Carruthers, Investor Relations of Ciphergen Biosystems, Inc.,
+1-510-505-2297 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024